Breast cancer (BC) is the most malignant cancer and the second leading cause of deaths in women worldwide. It is typically classified into the following three subtypes: estrogen receptor (ER)/progesterone receptor (PR)-positive (luminal), human epidermal growth factor receptor 2 (HER2)-amplified, and ER/PR/HER2-triple negative BC (TNBC). Tremendous progress has been made to understand molecular mechanisms underlying BC development, progression, and metastasis, and to develop molecule-targeted therapies for clinical applications. Yet, some molecular details are still missing, and the mortality rate of patients with luminal B BC or TNBC still remains high. Hence, it is important to search for more previously unknown genes or molecules responsible for...